Literature DB >> 21612331

Visceral adiposity as a target for the management of the metabolic syndrome.

Ken Kishida1, Tohru Funahashi, Yuji Matsuzawa, Iichiro Shimomura.   

Abstract

Atherosclerosis, the underlying cause of atherosclerotic cardiovascular disease (ACVD), develops due not only to a single cardiovascular risk factor but to a variety of complex factors. The concept of the multiple cardiometabolic risk factor clustering syndrome has been proposed as a highly atherogenic state, independent of hypercholesterolemia and smoking. Body fat distribution, especially visceral fat accumulation, is a major correlate of a cluster of diabetogenic, atherogenic, prothrombotic, and proinflammatory metabolic abnormalities referred to as the metabolic syndrome, with dysfunctional adipocytes and dysregulated production of adipocytokines (hypoadiponectinemia). Medical research has focused on visceral adiposity as an important component of the syndrome in Japanese subjects with a mild degree of adiposity compared with Western subjects. For the prevention of ACVD at least in Japan, it might be practical to stratify subjects with multiple risk factors for atherosclerotic cardiovascular disease based on visceral fat accumulation. Visceral fat reduction through health promotion programs using risk factor-oriented approaches may be effective in reducing ACVD events, as well as producing improvement in risks and hypoadiponectinemia. This review article discusses visceral adiposity as a key player in the syndrome. Visceral fat reduction with life-style modification is a potentially useful strategy in the prevention of ACVD in patients with the metabolic syndrome.

Entities:  

Mesh:

Year:  2011        PMID: 21612331     DOI: 10.3109/07853890.2011.564202

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  27 in total

1.  Treating diet-induced obesity: a new role for vagal afferents?

Authors:  Edward A Fox
Journal:  Dig Dis Sci       Date:  2012-03-22       Impact factor: 3.199

2.  Intermuscular and intramuscular adipose tissues: Bad vs. good adipose tissues.

Authors:  Gary J Hausman; Urmila Basu; Min Du; Melinda Fernyhough-Culver; Michael V Dodson
Journal:  Adipocyte       Date:  2014-12-10       Impact factor: 4.534

3.  In vivo precision of the GE Lunar iDXA for the measurement of visceral adipose tissue in adults: the influence of body mass index.

Authors:  M G Mellis; B Oldroyd; K Hind
Journal:  Eur J Clin Nutr       Date:  2014-10-15       Impact factor: 4.016

4.  A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus.

Authors:  Su-Jin Kim; Sehyun Chae; Hokeun Kim; Dong-Gi Mun; Seunghoon Back; Hye Yeon Choi; Kyong Soo Park; Daehee Hwang; Sung Hee Choi; Sang-Won Lee
Journal:  Mol Cell Proteomics       Date:  2014-01-08       Impact factor: 5.911

5.  Aortic cholesterol accumulation correlates with systemic inflammation but not hepatic and gonadal adipose tissue inflammation in low-density lipoprotein receptor null mice.

Authors:  Shu Wang; Bradley Miller; Nirupa R Matthan; Zeynep Goktas; Dayong Wu; Debra B Reed; Xiangling Yin; Paula Grammas; Naima Moustaid-Moussa; Chwan-Li Shen; Alice H Lichtenstein
Journal:  Nutr Res       Date:  2013-12       Impact factor: 3.315

6.  Low serum eicosapentaenoic acid / arachidonic acid ratio in male subjects with visceral obesity.

Authors:  Kana Inoue; Ken Kishida; Ayumu Hirata; Tohru Funahashi; Iichiro Shimomura
Journal:  Nutr Metab (Lond)       Date:  2013-03-12       Impact factor: 4.169

7.  Clinical significance of visceral fat reduction through health education in preventing atherosclerotic cardiovascular disease - Lesson from the Amagasaki Visceral Fat Study: A Japanese perspective.

Authors:  Ken Kishida; Tohru Funahashi; Iichiro Shimomura
Journal:  Nutr Metab (Lond)       Date:  2011-08-16       Impact factor: 4.169

8.  The Effect of Body Weight Changes on Total Plasma Clozapine Concentrations Determined by Applying a Statistical Model to the Data From a Double-Blind Trial.

Authors:  Francisco J Diaz; Richard C Josiassen; Jose de Leon
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

9.  Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients.

Authors:  Jenq-Wen Huang; Chung-Yi Yang; Hon-Yen Wu; Kao-Lang Liu; Chi-Ting Su; Cho-Kai Wu; Jen-Kuang Lee; Chih-Kang Chiang; Hui-Teng Cheng; Yu-Chung Lien; Kuan-Yu Hung
Journal:  Cardiovasc Diabetol       Date:  2013-06-08       Impact factor: 9.951

10.  Prevalence rate of Metabolic Syndrome in a group of light and heavy smokers.

Authors:  Hellas Cena; Antonella Tesone; Rosanna Niniano; Isa Cerveri; Carla Roggi; Giovanna Turconi
Journal:  Diabetol Metab Syndr       Date:  2013-05-30       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.